DayOne supports IPDx
Country of origin
IPDx proprietary technology translates the intricate collection of antibodies into actionable data to develop diagnostics that help detect disease earlier and guide treatment decisions.
IPDx’s core technology Mimotope Variation analysis (MVA) combines random peptide phage display library screening, next-generation sequencing, and big data analytics to decode antibody signatures.
Antibody screening. Biological samples (blood, urine, saliva etc.) containing antibodies are screened against peptide phage display library containing 1010 peptides, mimicking the billions of naturally occurring antigens. Phage DNA encoding the displayed peptide sequence is isolated from antibody-bound phages and sequenced to identify the antibody-bound epitope peptides.
Data analysis. Epitope peptide sequences are analyzed using advanced computational methods to identify disease-specific epitope/mimotope sequences and sequence motifs. The disease-specific epitope peptides and motifs may represent both antigens of functional antibodies involved in disease-causing pathways and antibodies that reflect downstream pathway changes related to the disease.
Their understanding of the antibody repertoire is ever-growing with each MVA analysis. Every consecutive analysis is added to their database enhancing the computational power of MVA and delivering further insight into disease mechanisms.
”DayOne delivered the workshops and most importantly opened up their network to help build and fine-tune my company's offering and strategy. Outside of the workshops, there are so many resources to take advantage of including coaches, industry experts, publicity, events, and moreChristoff NeumanCo-founder & Director of business development IPDx